Eylea Side Effects: Why Are IOI Cases on the Rise?
Regeneron’s eye drug Eylea has been one of the most commercially successful ophthalmology treatments on the market for years. Used widely to treat conditions including wet age related macular degeneration and diabetic macular edema, the drug has helped millions of patients preserve and improve their vision. But a growing number of reports of a rare post injection complication are raising questions that doctors and researchers have not yet been able to fully answer.
The Eylea side effects in question involve non infectious intraocular inflammation, known as IOI, a condition in which patients experience a sharp decline in vision and eye pain following an injection. The FDA received 71 reports of this complication in 2017 alone, nearly triple the total from 2014, which had previously been the highest on record. While the side effect is treatable and has not been associated with permanent vision loss, the upward trend has prompted concern among retinal specialists and industry analysts alike.
Putting the Numbers in Context
Regeneron has been quick to note that the increase in reported Eylea side effects must be viewed in the context of significantly expanded drug use. The company sold approximately 2.2 million vials of Eylea in 2017, compared to 1 million in 2014. The rate of IOI cases remains low in absolute terms, occurring in roughly 1 in 10,000 patients receiving the drug. Regeneron has also noted that this rate is lower than what was observed in the original clinical trials.
Still, analysts have flagged the pattern as worth monitoring. Jefferies analyst Biren Amin noted that the problem appears to be specific to Eylea. Archrival Lucentis from Roche reported between just six and 18 similar adverse events per year since 2012, leading Amin and colleagues to conclude that the IOI signal is unique to Eylea rather than a class wide phenomenon.
What Is Causing the Uptick
The American Society of Retina Specialists conducted an internal review and confirmed that the rise in Eylea side effects does not appear to be caused by a manufacturing error. Approximately 70 percent of identified clusters, defined as at least five cases within a 30 day period, involved multiple lots of the drug, ruling out a single contaminated batch as the source.
The ASRS noted that other variables may be playing a role, including syringe type and temperature variations during storage or handling. The organization reminded members that temperature control is particularly important for biologic drugs like Eylea, as even modest deviations from recommended storage conditions can alter drug properties in ways that affect tolerability.
Beyond those observations, the cause remains unknown. One Philadelphia based eye surgeon described the key open questions as frequency, severity, and risk factors. Most reported cases involve patients who had received previous injections, suggesting that prior exposure may increase susceptibility. However, some cases have also occurred after a single injection, meaning that prior exposure is not a prerequisite.
The Benefit Risk Balance Remains Favorable
Despite the unresolved questions around Eylea side effects, the medical community has been consistent in emphasizing that the drug’s benefits continue to substantially outweigh its risks. The ASRS stated this explicitly in a member communication, and a Johns Hopkins ophthalmology professor echoed the point, noting that the number of adverse events is small relative to the enormous benefit the treatment provides to patients who would otherwise face serious vision loss.
Regeneron has offered to replace unused vials for physicians on request and has stated that it is closely monitoring all reports of IOI. The company expressed confidence that Eylea’s extensive clinical data, broad label, and long term real world experience will sustain its position as a leading treatment option for years to come, even as competitive products from Novartis and Roche move through development.
For patients currently receiving Eylea injections who have concerns about Eylea side effects, the Mayo Clinic provides a helpful overview of macular degeneration treatment options and what to discuss with your physician.
Clinical Research in Ophthalmology and Retinal Disease
Understanding the mechanisms behind rare drug side effects, and developing safer and more effective alternatives, requires ongoing investment in ophthalmology clinical research. Retinal disease is one of the most active areas of drug development in medicine today, with multiple new agents and delivery mechanisms under investigation.
FOMAT supports ophthalmology and retina clinical research through a national network of investigator sites, including investigators with specialized expertise in retinal disease. To explore active studies, visit our patient active studies page. For more health and research insights, explore the FOMAT blogs and updates.